Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
Authors Chihoko Yoshimura, Hiromi Muraoka, Hiroaki Ochiiwa, Shingo Tsuji, Akihiro Hashimoto, Toru Takenaka, Hiromi Kazuno, Keiji Ishida, Takashi Mizutani, Shuichi Ohkubo, Kenichi Matsuo, Teruhiro Utsugi and Yoshikazu Iwasawa
Title TAS4464, a novel, highly potent, and selective inhibitor of NEDD8 activating enzyme demonstrates sustained target inhibition and antitumor activity in a preclinical model
Journal Mol Cancer Ther
Abstract Text Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C176


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
TAS4464 TAS4464 inhibits NEDD8 activating enzyme (NAE), therefore inhibits tumor cell growth (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C176).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown hematologic cancer not applicable TAS4464 Preclinical - Cell culture Actionable In a preclinical study, TAS4464 demonstrated cytotoxicity in a number of hematologic cancer cell lines in culture (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C176). detail...
Unknown unknown acute lymphoblastic leukemia not applicable TAS4464 Preclinical - Cell line xenograft Actionable In a preclinical study, TAS4464 resulted in complete tumor regression in cell line xenograft models of acute lymphocytic leukemia (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C176). detail...